Current status and treatment strategies for liver injury before targeted immunotherapy for liver cancer

VernacularTitle:肝癌靶免治疗前肝损伤的现状及处理策略
Author: Junmei JIA ¹ ; Jiangshan REN ; Liaoyun ZHANG
Author Information

1. 山西医科大学第一医院肿瘤科，太原　030001
Keywords: Hepatocellular carcinoma; Target-immunotherapy; Liver injury; Liver protection
From: Chinese Journal of Hepatology 2023;31(11):1133-1136
CountryChina
Language:Chinese
Abstract: The occurrence rate of primary liver cancer in malignant tumors ranks sixth in the world, and the mortality rate ranks third, with a poor prognosis and a five-year survival rate of less than 5%. Most patients with liver cancer in China are found to be in the intermediate and advanced stages, and a targeted immunotherapy combination has become the main treatment option. However, many patients have underlying liver lesions, and their liver function cannot meet the requirements of targeted immunotherapy, which directly affects the treatment of liver cancer patients. Therefore, it is very important to optimize the patient's liver function in a timely manner so as to obtain the opportunity for anti-tumor therapy. This article reviews the current status and response strategies before liver injury related to targeted immune therapy in patients with primary liver cancer.